ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has posted briefing documents for the Allergenic Products Advisory Committee meeting on 12 December to review Merck’s Biologic License Application (BLA) for the investigational grass sublingual allergy immunotherapy (AIT) tablet (marketed in Europe as GRAZAX®).
Help employers find you! Check out all the jobs and post your resume.
